Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Accurate assessment of TP53 gene status in sporadic tumors and in the germline of individuals at high risk of cancer due to Li–Fraumeni Syndrome (LFS) has important clinical implications for diagnosis, surveillance, and therapy. Genomic data from more than 20,000 cancer genomes provide a wealth of information on cancer gene alterations and have confirmed TP53 as the most commonly mutated gene in human cancer. Analysis of a database of 70,000 TP53 variants reveals that the two newly discovered exons of the gene, exons 9β and 9γ, generated by alternative splicing, are the targets of inactivating mutation events in breast, liver, and head and neck tumors. Furthermore, germline rearrange-ments in intron 1 of TP53 are associated with LFS and are frequently observed in sporadic osteosarcoma. In this context of constantly growing genomic data, we discuss how screening strategies must be improved when assessing TP53 status in clinical samples. Finally, we discuss how TP53 alterations should be described by using accurate nomenclature to avoid confusion in scientific and clinical reports. Cancer Res; 77(6); 1250–60. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067 · cited 1×
“In many tumor types, such as lung, gastric, high-grade serous ovarian, or breast carcinoma, TP53 variants are an early event that can be detected in ctDNA from patients with early-stage disease (47, 48).”
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Self-citationTP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Over the following years, there was a steady increase in the number of publications describing novel TP53 alterations in most cancer types, culminating in over 10,000 variants (encompassing about 2,500 distinct mutational events) reported in 300 publications by 2001 (7, 8).”
InfluentialSelf-citationThe p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Self-citationMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 1×
“Because of the extremely high frequency of missense variants, the oncogenic gain of function of many variants and the fact that cancer cells overexpress the mutant protein, TP53 is a promising target for the development of therapies designed to induce inhibition or restoration of p53 function by small molecules (49).”
Cited by
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Molinaro, E., Romei, C., Biagini, A., Sabini, E., Agate, L., Mazzeo, S., Materazzi, G., Sellari-Franceschini, S., Ribechini, A., Torregrossa, L., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.76 · Cited by 483
Yin, Z.-X., Hang, W., Liu, G., Wang, Y.-S., Shen, X.-F., Sun, Q.-H., Li, D.-D., Jian, Y.-P., Zhang, Y.-H., Quan, C.-S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.21277 · Cited by 19
Metadata
- Authors
- Leroy, B., Ballinger, M. L., Baran-Marszak, F., Bond, G. L., Braithwaite, A., Concin, N., Donehower, L. A., El-Deiry, W. S., Fenaux, P., Gaidano, G., Langerød, A., Hellstrom-Lindberg, E., Iggo, R., Lehmann-Che, J., Mai, P. L., Malkin, D., Moll, U. M., Myers, J. N., Nichols, K. E., Pospisilova, S., Ashton-Prolla, P., Rossi, D., Savage, S. A., Strong, L. C., Tonin, P. N., Zeillinger, R., Zenz, T., Fraumeni, J. F., Taschner, P. E. M., Hainaut, P., & Soussi, T.
- Venue
- Cancer Research
- Published
- 2017-03-14
- Volume
- 77
- Issue
- 6
- Pages
- 1250-1260
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2591837371
- Cited by
- 91
- References
- 24
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-2179
- The paper
- Leroy, B., Ballinger, M. L., Baran-Marszak, F., Bond, G. L., Braithwaite, A., Concin, N., Donehower, L. A., El-Deiry, W. S., Fenaux, P., Gaidano, G., Langerød, A., Hellstrom-Lindberg, E., Iggo, R., Lehmann-Che, J., Mai, P. L., Malkin, D., Moll, U. M., Myers, J. N., Nichols, K. E., . . . Soussi, T. (2017). Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-2179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.